Abstract: Presently provided are inhibitors of TD02 and IDO1 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.

Abstract: Disclosed embodiments may include a method for using accounts with multiple profiles where the system allows a primary user to create one or more secondary user profiles. Each secondary user profile is associated with its own VCN and one or more attributes. The one or more attributes can be used to limit the spending ability of each secondary user individually with hard and soft spending limits including merchant category, overall spending, and geographic limits. Purchases by a secondary user that violate the soft limits may be allowed by the primary user using an application associated with the primary account number. Attributes can be assembled by the primary user to create specific and creative spending limits. The system associates each transaction with the user profile using the specific VCN and generates a GUI for the primary user showing the second user profile, its current balance, and transaction history.

Abstract: This invention provides, among other things, compounds useful for treating spirochete diseases such as Lyme disease, as well as pharmaceutical formulations and/or environmental baits containing such compounds.

Abstract: Managing insurance policy processing includes: receiving a set of insurance policy hold criteria specifying an insurance policy hold, the insurance policy hold criteria comprising an insurance policy hold period during which the insurance policy hold is in effect; receiving a request to execute an insurance policy processing operation on an insurance policy; determining, based at least in part on the set of policy hold criteria, that the insurance policy processing operation is subject to the insurance policy hold; disallowing the insurance policy processing operation from being executed; determining that the insurance policy hold is to be released; and allowing the insurance policy hold to be released.

Abstract: The present invention relates to unique isoforms of eukaryotic initiation Factor 5A (“eIF-5A”): senescence-induced eIF-5A; wounding/pathogen induced eIF-5A; stress eIF-5A and growth eIF-5A, as well as polynucleotides that encode these three factors. The present invention also relates to methods involving modulating the expression of these factors. The present invention also relates to deoxyhypusine synthase (“DHS”), polynucleotides that encode DHS, and methods involving modulating the expression of DHS.

Abstract: The present invention relates to unique isoforms of eukaryotic initiation Factor 5A (“eIF-5A”): senescence-induced eIF-5A; wounding/pathogen induced eIF-5A; stress eIF-5A and growth eIF-5A, as well as polynucleotides that encode these three factors. The present invention also relates to methods involving modulating the expression of these factors. The present invention also relates to deoxyhypusine synthase (“DHS”), polynucleotides that encode DHS, and methods involving modulating the expression of DHS.

Abstract: The present invention relates to novel method of vacuum infiltration transformation of plants which provides an increased efficiency of transformation over previously known vacuum infiltration methods, as well as seeds, plants and plant parts transformed with the methods.

Abstract: The present invention relates to unique isoforms of eukaryotic initiation Factor 5A (“eIF-5A”): senescence-induced eIF-5A; wounding/pathogen induced eIF-5A; stress eIF-5A and growth eIF-5A, as well as polynucleotides that encode these three factors. The present invention also relates to methods involving modulating the expression of these factors. The present invention also relates to deoxyhypusine synthase (“DHS”), polynucleotides that encode DHS, and methods involving modulating the expression of DHS.